0000950103-26-007252
SEC filingAC Immune S.A. announces board governance changes including appointment of Lead Independent Director and Audit Committee member ahead of its 2026 AGM on June 11, with Dr. Andrea Pfeifer retiring as CEO.
The filing discloses key governance enhancements with Dr. Monika Bütler's appointment as Lead Independent Director to oversee board independence amid Martin Zügel's dual role as Chair and Interim CEO following Dr. Andrea Pfeifer's retirement after 23 years. Dr. Carl June's addition to the Audit & Finance Committee ensures compliance with the minimum three-member requirement. These changes coincide with the 2026 AGM agenda, proposing approval of 2025 financials showing a CHF 70,447K IFRS net loss, discharge of board and management, binding votes on compensation caps, re-elections of board members excluding Pfeifer, and amendments to articles for a capital band and increased conditional share capital for employee plans. Signed by Andrea Pfeifer as CEO and Christopher Roberts as CFO on May 15, 2026.